Progestogen use in women approaching the menopause and breast cancer risk

Maturitas

Volumn 62, Issue 4, 2009, Pages 338-342

  Campagnoli, Carlo ^a   Ambroggio, Simona ^a   Lotano, Maria Rosa ^a   Peris, Clementina ^a  

^a SC Ginecologia Endocrinologica Ospedale Ostetrico Ginecologico   (Italy)

Author keywords

Breast cancer; Hormone therapy; Menopausal transition; Progestogens

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER RISK; HORMONAL THERAPY; HUMAN; MENOPAUSE; PREMENOPAUSE; REVIEW;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PREMENOPAUSE; PROGESTINS; RISK FACTORS;

EID: 67349214059     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.10.017     Document Type: Review

References (51)

1. Clarke R.B. Ovarian steroids and the human breast: regulation of stem cells and cell proliferation. Maturitas 54 (2006) 327-334
2. Kuhl H. Pharmacology of estrogens and progestins: influence of different routes of administration. Climacteric 8 S1 (2005) S3-S63
3. Leo J.C.L., and Lin V.C.N. The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner. Int J Cancer 122 (2008) 230-243
4. Seeger H., and Mueck A.O. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 109 (2008) 11-15
5. Wiebe J.P. Progesterone metabolites in breast cancer. Endocr Relat Cancer 13 (2006) 717-738
6. Pasqualini J.R. Progestins and breast cancer. Gynecol Endocrinol 23 S1 (2007) 32-41
7. Wood C.E., Register T.C., Lees C.J., Chen H., Kimrey S., and Cline J.M. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101 (2007) 125-134
8. Campagnoli C., Clavel-Chapelon F., Kaaks R., Peris C., and Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96 (2005) 95-108
9. Eliassen A.H., Missmer S.A., Tworoger S.S., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98 (2006) 1406-1415
10. Micheli A., Muti P., Secreto G., et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112 (2004) 312-318
11. Kaaks R., Berrino F., Key T., et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97 (2005) 755-765
12. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
13. Fournier A., Fabre A., Mesrine S., Boutron-Ruault M.C., Berrino F., and Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26 (2008) 1260-1268
14. Collins J.A., Blake J.M., and Crosignani P.G. Breast cancer risk with postmenopausal hormone treatment. Hum Reprod Update 11 (2005) 545-560
15. Reeves G.K., Beral V., Green J., Gathani T., and Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7 (2006) 910-918
16. Biglia N., Mariani L., Sgro L., Mininanni P., Moggio G., and Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 14 (2007) 549-567
17. Li C.I., Malone K.E., Porter K.E., et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 17 (2008) 43-50
18. Speroff L. The perimenopausal transition. Ann NY Acad Sci 900 (2000) 375-392
19. Practice Committee of the American Society for Reproductive Medicine. The menopausal transition. Fertil Steril 86 S5 (2006) S253-S256
20. Jain A., and Santoro N. Endocrine mechanisms and management for abnormal bleeding due to perimenopausal changes. Clin Obstet Gynecol 48 (2005) 295-331
21. Duckitt K. Medical management of perimenopausal menorrhagia: an evidence-based approach. Menopause Int 13 (2007) 14-18
22. Hickey M., Higham J., and Fraser I.S. The Cochrane Database of Systemic Reviews- Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Libr. 2 (2008)
23. Schweppe K.W. Long-term use of progestogens-effect on endometriosis, adenomyosis and myomas. Gynecol Endocrinol 23 S1 (2007) 17-21
24. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 75 S6 (2007) 155-160
25. Goehring C., and Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 19 (1997) 310-327
26. Winkler U.H., Schindler A.E., Brinkmann U.S., Ebert C., and Oberhoff C. Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol Endocrinol 15 S6 (2001) 37-43
27. Courtillot C., Plu-Bureau G., Binart N., et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 10 (2005) 325-335
28. Lowy I., and Weisz G. French hormones: progestins and therapeutic variation in France. Soc Sci Med 60 (2005) 2609-2622
29. Lopès P., and Schatz B. Propause survey: profile of patients treated with progestins in perimenopause. J Gynecol Obstet Biol Reprod (Paris) 34 (2005) 232-240
30. Ringa V., Fritel X., Varnoux N., Zins M., Piault S., and Quelen C. Association between premenopausal progestogen use and postmenopausal hormone therapy in the GAZEL cohort. Maturitas 58 (2007) 216-225
31. Plu-Bureau G., Le M.G., Sitruk-Ware R., Thalabard J.C., and Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 70 (1994) 270-277
32. Fabre A., Fournier A., Mesrine S., et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 96 (2007) 841-844
33. McNaught J., Reid R.L., Provencher D.M., et al. Progesterone-only and non-hormonal contraception in the breast cancer survivor: joint review and committee opinion of the Society of Obstetricians and Gynaecologist of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Cancer 28 (2006) 616-626
34. Sitruk-Ware R., and Plu-Bureau G. Exogenous progestagens and the human breast. Maturitas 49 (2004) 58-66
35. Plu-Bureau G., Le M., Thalabard J.C., Sitruk-Ware R., and Mauvais-Jarvis P. Percutaneous progesterone uses and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev 23 (1999) 290-296
36. Fabre A., Fournier A., Mesrine S., et al. Progestagens use before menopause and breast cancer risk according to histology and hormone-receptors. Cancer Epidemiol Biomarkers Prev 17 (2008) 2723-2728
37. Prentice R.L., Chlebowski R.T., Stefanick M.L., et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167 (2008) 1207-1216
38. Prentice R.L., Chlebowski R.T., Stefanick M.L., et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 167 (2008) 1407-1415
39. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
40. Flesch-Janys D., Slanger T., Mutschelknauss E., et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123 (2008) 933-941
41. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46 (2003) S7-S16
42. Campagnoli C., Abbà C., Ambroggio S., Lotano M.R., and Peris C. Differential effects of various progestogens on metabolic risk factors for breast cancer. Gynecol Endocrinol 23 S1 (2007) 22-31
43. Campagnoli C., Pasanisi P., Peris C., and Berrino F. Insulin-like Growth Factor-I and breast cancer: epidemiological and clinical data. In: Pasqualini J.R. (Ed). Breast cancer: prognosis, treatment and prevention. 2nd ed. (2008), Informa Healthcare, New York 323-342
44. Birrell S.N., Butler L.M., Harris J.M., Buchanan G., and Tilley W.D. Disruption of androgen receptor signaling by sinthetic progestins may increase risk of developing breast cancer. FASEB J 21 (2007) 2285-2293
45. Gompel A., and Courtin A. Progesterone receptors isoforms and human breast cancer. In: Pasqualini J.R. (Ed). Breast cancer: prognosis, treatment and prevention. 2nd ed. (2008), Informa Healthcare, New York 113-122
46. Stanczyk F.Z. All progestins are not created equal. Steroids 68 (2003) 879-890
47. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disorders 3 (2002) 211-214
48. Mersin H., Yildirim E., Gulben K., and Berberoglu U. Is invasive lobular carcinoma different from invasive ductal carcinoma?. EJSO 29 (2003) 390-395
49. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
50. Prior J.C. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 26 (2005) 297-300
51. Moen M.H., Kahn H., Bjerve K.S., and Halvorsen T.B. Menometrorrhagia in the perimenopause is associated with increased serum estradiol. Maturitas 47 (2004) 151-155